Global Liposome Assisted Drug Delivery Market Research Report 2024
Published on: 2024-01-04 | No of Pages : 400 | Industry : Medical
Publisher : MRA | Format : PDF
Global Liposome Assisted Drug Delivery Market Research Report 2024
Liposomes have been used to improve the therapeutic index of new or established drugs by modifying drug absorption, reducing metabolism, prolonging biological half-life or reducing toxicity. Drug distribution is then controlled primarily by properties of the carrier and no longer by physico-chemical characteristics of the drug substance only.
According to MRAResearch’s new survey, global Liposome Assisted Drug Delivery market is projected to reach US$ million in 2033, increasing from US$ million in 2022, with the CAGR of % during the period of 2023 to 2033. Influencing issues, such as economy environments, COVID-19 and Russia-Ukraine War, have led to great market fluctuations in the past few years and are considered comprehensively in the whole Liposome Assisted Drug Delivery market research.
Key companies engaged in the Liposome Assisted Drug Delivery industry include Gilead Sciences, Pacira, Sun Pharmaceutical, Johnson & Johnson, Luye Pharma, Sigma-Tau Group, Ipsen (Onivyde), CSPC and Teva Pharmaceutical, etc. Among those companies, the top 3 players guaranteed % supply worldwide in 2022.
When refers to consumption region, % value of Liposome Assisted Drug Delivery were sold to North America, Europe and Asia Pacific in 2022. Moreover, China, plays a key role in the whole Liposome Assisted Drug Delivery market and estimated to attract more attentions from industry insiders and investors.
Report Scope
This report, based on historical analysis (2018-2022) and forecast calculation (2023-2033), aims to help readers to get a comprehensive understanding of global Liposome Assisted Drug Delivery market with multiple angles, which provides sufficient supports to readers’ strategy and decision making.
Gilead Sciences
Pacira
Sun Pharmaceutical
Johnson & Johnson
Luye Pharma
Sigma-Tau Group
Ipsen (Onivyde)
CSPC
Teva Pharmaceutical
Novartis
Fudan-Zhangjiang
Segment by Type
Liposomal Doxorubicin
Liposomal Amphoteracin B
Liposomal Paclitaxel
Others
Fungal Infection Therapy
Cancer & Tumor Therapy
Others
By Region
North America
United States
Canada
Europe
Germany
France
UK
Italy
Russia
Nordic Countries
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA
The Liposome Assisted Drug Delivery report covers below items
Chapter 1Product Basic Information (Definition, Type and Application)
Chapter 2Global market size, regional market size. Market Opportunities and Challenges
Chapter 3Companies’ Competition Patterns
Chapter 4Product Type Analysis
Chapter 5Product Application Analysis
Chapter 6 to 10Country Level Value Analysis
Chapter 11Companies' Outline
Chapter 12Market Conclusions
Chapter 13Research Methodology and Data Source
According to MRAResearch’s new survey, global Liposome Assisted Drug Delivery market is projected to reach US$ million in 2033, increasing from US$ million in 2022, with the CAGR of % during the period of 2023 to 2033. Influencing issues, such as economy environments, COVID-19 and Russia-Ukraine War, have led to great market fluctuations in the past few years and are considered comprehensively in the whole Liposome Assisted Drug Delivery market research.
Key companies engaged in the Liposome Assisted Drug Delivery industry include Gilead Sciences, Pacira, Sun Pharmaceutical, Johnson & Johnson, Luye Pharma, Sigma-Tau Group, Ipsen (Onivyde), CSPC and Teva Pharmaceutical, etc. Among those companies, the top 3 players guaranteed % supply worldwide in 2022.
When refers to consumption region, % value of Liposome Assisted Drug Delivery were sold to North America, Europe and Asia Pacific in 2022. Moreover, China, plays a key role in the whole Liposome Assisted Drug Delivery market and estimated to attract more attentions from industry insiders and investors.
Report Scope
This report, based on historical analysis (2018-2022) and forecast calculation (2023-2033), aims to help readers to get a comprehensive understanding of global Liposome Assisted Drug Delivery market with multiple angles, which provides sufficient supports to readers’ strategy and decision making.
By Company
Gilead Sciences
Pacira
Sun Pharmaceutical
Johnson & Johnson
Luye Pharma
Sigma-Tau Group
Ipsen (Onivyde)
CSPC
Teva Pharmaceutical
Novartis
Fudan-Zhangjiang
Segment by Type
Liposomal Doxorubicin
Liposomal Amphoteracin B
Liposomal Paclitaxel
Others
Segment by Application
Fungal Infection Therapy
Cancer & Tumor Therapy
Others
By Region
North America
United States
Canada
Europe
Germany
France
UK
Italy
Russia
Nordic Countries
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA
The Liposome Assisted Drug Delivery report covers below items
Chapter 1Product Basic Information (Definition, Type and Application)
Chapter 2Global market size, regional market size. Market Opportunities and Challenges
Chapter 3Companies’ Competition Patterns
Chapter 4Product Type Analysis
Chapter 5Product Application Analysis
Chapter 6 to 10Country Level Value Analysis
Chapter 11Companies' Outline
Chapter 12Market Conclusions
Chapter 13Research Methodology and Data Source